MGUS: Risk of Progression to Multiple Myeloma Can Change Over Time
A risk signature is not constant in a given patient over time—it is subject to change depending on a variety of factors.
Brain Cancer
BRAIN CANCER ADVISOR
FEATURED CONTENT
-
-
ACP Releases Policy Statement on DOI, COI Management for Clinical Guideline Development
The American College of Physicians endorses the necessity of a comprehensive process for disclosure of potential conflicts of interest to ensure the integrity of clinical guidelines and guidance statements. -
Previously Hidden FDA Data Reveal a Multitude of Adverse Events Linked to Breast Implants
Why were adverse events reported through an alternative reporting channel as opposed to a more transparent means? -
Personalized Cancer Vaccine NEO-PV-01 Shows Promise in 3 Types of Advanced Cancer
Early results from a clinical trial of personalized cancer vaccine NEO-PV-01 in 3 types of advanced cancer have shown promise and no significant toxicity issues. -
Looking at Survival Differently in Patients With Metastatic Kidney Cancer
Conditional survival may more accurately assess prognosis than traditional survival for patients with metastatic kidney cancer, but the metric is not without its caveats.
BRAIN CANCER NEWS
Treatment Reduction in Intermediate-Risk Neuroblastoma Deemed Successful
Outcomes Poor Years After Radiation for Pediatric Glioma Survivors
LIBRETTO-121: A Phase 1/2 Trial Investigating LOXO-292 in Pediatric Patients With Advanced Solid or Primary CNS Tumors
Computer-Assisted Diagnosis Aids Detection of Glioma Growth
Entrectinib Shows Activity in Pediatric Brain Tumors and Other Solid Tumors
Want to read more?
Please login or register first to view this content.
